(VIANEWS) – Shares of Zai Lab (NASDAQ: ZLAB) rose by a staggering 10.25% to $39.47 at 11:50 EST on Thursday, following the last session’s downward trend. NASDAQ is jumping 1.34% to $12,088.78, after three successive sessions in a row of losses. This seems, as yet, an all-around positive trend exchanging session today.
Zai Lab’s last close was $35.80, 33.64% below its 52-week high of $53.95.
About Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Earnings Per Share
As for profitability, Zai Lab has a trailing twelve months EPS of $-4.96.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.05%.
Yearly Top and Bottom Value
Zai Lab’s stock is valued at $39.47 at 11:50 EST, way below its 52-week high of $53.95 and way above its 52-week low of $20.98.
Sales Growth
Zai Lab’s sales growth is 27.6% for the ongoing quarter and 40.9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.5%, now sitting on 196.61M for the twelve trailing months.
Volatility
Zai Lab’s last week, last month’s, and last quarter’s current intraday variation average was 2.57%, 0.40%, and 3.61%.
Zai Lab’s highest amplitude of average volatility was 5.02% (last week), 3.78% (last month), and 3.61% (last quarter).
More news about Zai Lab (ZLAB).
